News Posts List
GU ASCO: The Role of Cytoreductive Nephrectomy
02/03/2012
By: Thomas Powles, MD The introduction of agents targeting angiogenesis and the mTOR pathway have substantially improved the outcome of metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy remains the standard of care in the era of targeted therapy. This is based on data from two randomized trials comparing nephrectomy and immune therapy with immune therapy alone.
Dilemma of the Small Renal Mass
02/03/2012
2012 Genitourinary Cancers Symposium Daily News: By: Sima Porten, MD, MPH, and Maxwell V. Meng, MD The past decade has seen significant advances in the treatment of patients with renal cell carcinoma, with the widespread adoption of minimally invasive surgical techniques and the approval of several targeted systemic agents for metastatic disease.
Papillary Kidney Cancer Clinical Trials
02/03/2012
This page is dedicated to bringing you the most current information about clinical trials for papillary kidney cancer. In a small number of cases, papillary renal cell carcinoma is hereditary. This disease accounts for a small percentage of all cases of kidney cancer.
AGS-003 with sunitinib and overall survival
02/02/2012
AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival
Kidney Papillary Carcinoma
02/02/2012
Kidney clear cell carcinoma is the most common type of kidney cancer, representing approximately 92 percent of such cases. Papillary carcinoma accounts for about 8 percent.
Thermal ablation of renal cell carcinoma
02/01/2012
The incidence of renal cell carcinoma (RCC) is increasing. With the increasing emphasis on minimally invasive nephron-sparing surgery, thermal ablation is playing a larger role in the management of patients with this disease.
2012 GU ASCO "Daily News"
02/01/2012
The Kidney Cancer Association is podcasting live from the 2012 Genitourinary Cancers Symposium, in San Francisco. For the latest information from this event,be sure to read the "Daily News" online.
Quality of life during dendritic cell vaccination
02/01/2012
The data indicate that dendritic cells (DCs) vaccination, which is a personalised treatment modality, maintains quality of life (QoL) and thus represents an attractive nontoxic treatment option for patients with metastatic renal cell carcinoma (RCC).
Vaccine Therapy With or Without Fludarabine
02/01/2012
This randomized phase II trial is studying vaccine therapy and fludarabine to see how well they work compared to vaccine therapy alone in treating patients with stage IV kidney cancer.
Small Renal Oncocytomas
02/01/2012
To evaluate characteristic imaging findings of tumor attenuation in multiphase computed tomography (CT) between renal oncocytomas and clear-cell renal cell carcinoma (ccRCC) of small tumor size (
News Feed